Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai(National Institutes of Health), William L. Dahut(Dana-Farber Cancer Institute), Akira Yuno(National Institutes of Health), Ryan Dittamore(Epic Sciences (United States)), Paul S. Meltzer(National Human Genome Research Institute), Maria J. Merino(National Institutes of Health), Jennifer L. Marté(National Cancer Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Jane B. Trepel, Amy Hankin(National Institutes of Health), Seth M. Steinberg(National Cancer Institute), Ravi A. Madan(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Renee N. Donahue(National Institutes of Health), Kathleen Kelly(Center for Cancer Research), Jeffrey Schlom(National Cancer Institute), Keith Killian(National Institutes of Health), Venkatesh Krishnasamy(National Institutes of Health), James L. Gulley(National Institutes of Health), David James VanderWeele(University of Chicago), Anna Couvillon(National Institutes of Health), Jung Min Lee(National Institutes of Health), Sunmin Lee(National Institutes of Health), Helen Owens(National Institutes of Health), E. Hitt Nichols(Leidos (United States)), Min-Jung Lee(National Institutes of Health), Michael L. Beshiri(National Cancer Institute)
Journal for ImmunoTherapy of Cancer
December 1, 2018
Cited by 312


Related Papers